What you already know about China-based Dagong Credit Rating is that it’s caused quite the kerfuffle over sovereign debt ratings by ranking China higher than the US and other developed countries, like the UK and Japan, based on a formula assigning more weight to the fiscal health and GDP growth of countries.
What you may not know is that last year Dagong officially applied to the SEC to become a Nationally Recognized Statistical Rating Organization (NRSRO), of which now there are only 10 (all of which are either North America- or Japan-based), and now claims to be getting the run around.
According to Fortune:
“This is stirring stuff. But as is often the case with news out of China, the latest Dagong statement itself is a bit of a riddle. Has the firm actually been rejected, as it contends, or is Dagong simply posturing?
“An outright U.S. rejection seems unlikely. The firm applied in December 2009 with the Securities and Exchange Commission for status as a Nationally Recognized Statistical Rating Organization, or NRSRO – the designation under which Moody’s, S&P, Fitch and several other agencies have registered with the SEC.
“Dagong sought the NRSRO label even though it has no U.S. offices, rates no U.S. companies and has no U.S. customers. As a result, the SEC said it would have to hold hearings to determine ‘whether Dagong has a sufficient connection with U.S. interstate commerce to register as an NRSRO.’
“In April, the SEC said it aimed to settle the question by July, but the next month the commission extended that deadline to Sept. 23. The commission hasn’t issued a ruling, an SEC spokesman said Wednesday, and isn’t likely to do so till September — which seems to rule out the ‘rejection’ the China Daily article speaks of.”
Part of what’s interesting about this latest twist is that Dagong, which makes the point of having “global” in its name, wants to be “nationally recognized” in the US despite, as noted above, having little connection to the nation. Of course, the NRSRO agencies – well, at least Moody’s, Standard & Poor’s, and Fitch Ratings — have influence far beyond US borders… and at least Canada and Japan have both jumped on the NRSRO bandwagon… but it’s hard to see what advantages they’ve gained as foreign organizations designated NRSROs.
You can read more details in Fortune’s coverage of how China’s Dagong says the US rejects it.
Rocky Vega,The Daily Reckoning
Rocky Vega is publisher of Agora Financial International, where he advances the growth of Agora Financial publishing enterprises outside of the US. Previously, he was publisher of The Daily Reckoning, and founding publisher of both UrbanTurf and RFID Update -- which he ran from Brazil, Chile, and Puerto Rico -- as well as associate publisher of FierceFinance. Rocky has an honors MS from the Stockholm School of Economics and an honors BA from Harvard University, where he served on the board of directors for Let?s Go Publications, Harvard Student Agencies, and The Harvard Advocate.
The present rating agencies (S&P, Moody’s et al) seems to suffer from a conflict of interest – they get paid by the same corporations to rate them. And dare they rate the US as it is? Not unless they want to commit financial suicide.
So, if Dagong were to rate the US corporations on its own (paid for by users), it would be more objective than what we have now. The sooner the SEC grant NRSRO status the better. More competition (after all, the US likes to claim that it is an open market) and a different perspective will make the ratings less biased, thereby benefiting the general public.
Gold has had a rough go of it since the 2008 financial crisis. But according to Matt Insley, there is now a very clear price floor for the yellow metal. And what's more interesting, he comes to this conclusion by way of a glass of chocolate milk and Janet Yellen's actions from here throne at the Eccles Building. Read on...
The recent spate of new tech-based IPOs has a few prominent investors (Ahem... David Einhorn) touting the return of the '90s tech bubble. But there are some very good reasons why this market is nothing like the '90s, and why investors should be wary of any advice to the contrary. Paul Mampilly explains...
Generic drugs are supposed to lower healthcare costs and provide you with another medical alternative. That's what it says on paper. But there's a real danger that goes along with these drugs. A danger even your doctor might not be aware of... Dr. David Eifrig has the full story. Read on...
The solar panel turns 60 on Friday, but this birthday celebration will be unlike any other the industry has seen so far. In the past, solar energy's high price tag meant its wide-spread usage was nothing more than a pipe dream. But now, after six decades, solar power may finally be cheaper than oil and Asian liquefied-natural-gas. Greg Guenthner has more...
Since the invention of the "shareholder rights plan" (i.e. the "poison pill"), most companies are relatively immune to hostile takeovers. But according to Dave Gonigam that could all change thanks to one activist investor. And if you're savvy enough, you may just be able to follow his lead for big gains. Read on...